We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA AdComms Give Thumbs-Up to Rexulti for Dementia Agitation
FDA AdComms Give Thumbs-Up to Rexulti for Dementia Agitation
A joint FDA advisory committee has cleared the way for Otsuka and Lundbeck’s Rexulti (brexpiprazole) as a new treatment for dementia-related agitation.